project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9ND; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.43; rna integrity number: 8.5; age at index: 55; days to birth: -20428; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1958; age at diagnosis: 20428; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 410.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 283; initial weight: 80.0; sample id: 949f85dd-0d5d-4b3f-a7a9-a2ddc5becf3b; sample submitter id: TCGA-ZG-A9ND-01A; portion id: 59651b5c-35d5-4240-8cf5-54c6c2931934; portion submitter id: TCGA-ZG-A9ND-01A-11; slide id: 9ddef1f8-a719-4fcd-b6f2-eeecd747b9d5; slide submitter id: TCGA-ZG-A9ND-01A-01-TS1; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 85.0; percent tumor nuclei: 85.0; section location: TOP;